PURPOSE: To evaluate the associations between plasma-soluble Fas ligand (sFasL) and age-related macular degeneration (AMD). METHODS: Plasma samples were obtained from 230 individuals (age range, 45-85), with or without AMD. The concentrations of sFasL were determined by an enzyme-linked immunosorbent assay (ELISA). The measured sFasL levels were transformed into cubic roots and were fitted into linear regression models against AMD status, with adjustment for age and sex. RESULTS: Plasma sFasL increased with age and AMD. There was a linear correlation between age and the cubic roots of sFasL. The plasma sFasL concentrations in non-AMD subjects ranged from 0 to 1.63 ng/mL (median, 0.69 ng/mL), whereas in patients with AMD, sFasL ranged from 0 to 2.43 ng/mL (median, 0.18 ng/mL). Between the ages of 61 and 84, the subjects with AMD had significantly higher sFasL than did the non-AMD subjects. There was a sexual dimorphism of the plasma sFasL levels. In non-AMD subjects, sFasL was lower in the females. In patients with AMD, sFasL was higher in the females. CONCLUSIONS: An elevation of plasma sFasL with aging may play a role in the development of AMD and is a potential peripheral marker for monitoring disease progression.
PURPOSE: To evaluate the associations between plasma-soluble Fas ligand (sFasL) and age-related macular degeneration (AMD). METHODS: Plasma samples were obtained from 230 individuals (age range, 45-85), with or without AMD. The concentrations of sFasL were determined by an enzyme-linked immunosorbent assay (ELISA). The measured sFasL levels were transformed into cubic roots and were fitted into linear regression models against AMD status, with adjustment for age and sex. RESULTS: Plasma sFasL increased with age and AMD. There was a linear correlation between age and the cubic roots of sFasL. The plasma sFasL concentrations in non-AMD subjects ranged from 0 to 1.63 ng/mL (median, 0.69 ng/mL), whereas in patients with AMD, sFasL ranged from 0 to 2.43 ng/mL (median, 0.18 ng/mL). Between the ages of 61 and 84, the subjects with AMD had significantly higher sFasL than did the non-AMD subjects. There was a sexual dimorphism of the plasma sFasL levels. In non-AMD subjects, sFasL was lower in the females. In patients with AMD, sFasL was higher in the females. CONCLUSIONS: An elevation of plasma sFasL with aging may play a role in the development of AMD and is a potential peripheral marker for monitoring disease progression.
Authors: Hui Zhao; Jayeeta Roychoudhury; Teresa A Doggett; Rajendra S Apte; Thomas A Ferguson Journal: Invest Ophthalmol Vis Sci Date: 2013-08-07 Impact factor: 4.799
Authors: Tamas Kiss; Ádám Nyúl-Tóth; Rafal Gulej; Stefano Tarantini; Tamas Csipo; Derek M Huffman; Anna Csiszar; Zoltan Ungvari; Peter Mukli; Anna Ungvari; Priya Balasubramanian; Andriy Yabluchanskiy; Zoltan Benyo; Shannon M Conley; Jonathan D Wren; Lori Garman Journal: Geroscience Date: 2022-02-05 Impact factor: 7.581
Authors: Aaron M Newman; Natasha B Gallo; Lisa S Hancox; Norma J Miller; Carolyn M Radeke; Michelle A Maloney; James B Cooper; Gregory S Hageman; Don H Anderson; Lincoln V Johnson; Monte J Radeke Journal: Genome Med Date: 2012-02-24 Impact factor: 11.117
Authors: Anu Kauppinen; Jussi J Paterno; Janusz Blasiak; Antero Salminen; Kai Kaarniranta Journal: Cell Mol Life Sci Date: 2016-02-06 Impact factor: 9.261